Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rae

Showing results (201-210 of 292) with videos related to

Pageof 30
Sort By:
Environmental Microbiology|August 14, 2021
Microbial community composition controls carbon flux across litter types in early phase of litter decompositionMarie E Kroeger, M Rae DeVan, Jaron Thompson, et al.
Breast Cancer Research and Treatment|July 22, 2017
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based studyD L Hertz, K M Kidwell, S G Hilsenbeck, et al.
Molecular Oncology|August 16, 2015
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analysesDaniel L Hertz, Kelley M Kidwell, Jacklyn N Thibert, et al.
American Journal of Epidemiology|December 19, 2016
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of HeterozygosityThomas P Ahern, Daniel L Hertz, Per Damkier, et al.
Frontiers in Genetics|July 2, 2021
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast CancerDaniel L Hertz, Karen Lisa Smith, Yuhua Zong, et al.
British Journal of Cancer|May 26, 2022
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancerAnna R Michmerhuizen, Lynn M Lerner, Connor Ward, et al.
Clinical & Experimental Metastasis|February 1, 2005
LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell linesErik W Thompson, Mark Waltham, Susan J Ramus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2024
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast CancerLajos Pusztai, Jess R Hoag, Kathy S Albain, et al.
Breast Cancer Research and Treatment|June 24, 2017
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patientsDaniel L Hertz, Kelly A Speth, Kelley M Kidwell, et al.
Pharmacogenetics and Genomics|June 7, 2021
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activityDaniel L Hertz, Julie A Douglas, Kelley M Kidwell, et al.
Pageof 30

Showing results (201-210 of 292) with videos related to

Sort By:
Pageof 30
Environmental Microbiology|August 14, 2021
Microbial community composition controls carbon flux across litter types in early phase of litter decompositionMarie E Kroeger, M Rae DeVan, Jaron Thompson, et al.
Breast Cancer Research and Treatment|July 22, 2017
CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based studyD L Hertz, K M Kidwell, S G Hilsenbeck, et al.
Molecular Oncology|August 16, 2015
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analysesDaniel L Hertz, Kelley M Kidwell, Jacklyn N Thibert, et al.
American Journal of Epidemiology|December 19, 2016
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of HeterozygosityThomas P Ahern, Daniel L Hertz, Per Damkier, et al.
Frontiers in Genetics|July 2, 2021
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast CancerDaniel L Hertz, Karen Lisa Smith, Yuhua Zong, et al.
British Journal of Cancer|May 26, 2022
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancerAnna R Michmerhuizen, Lynn M Lerner, Connor Ward, et al.
Clinical & Experimental Metastasis|February 1, 2005
LCC15-MB cells are MDA-MB-435: a review of misidentified breast and prostate cell linesErik W Thompson, Mark Waltham, Susan J Ramus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2024
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast CancerLajos Pusztai, Jess R Hoag, Kathy S Albain, et al.
Breast Cancer Research and Treatment|June 24, 2017
Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patientsDaniel L Hertz, Kelly A Speth, Kelley M Kidwell, et al.
Pharmacogenetics and Genomics|June 7, 2021
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activityDaniel L Hertz, Julie A Douglas, Kelley M Kidwell, et al.
Pageof 30